New Immunotherapy for Respiratory Papillomatosis

Adults with recurrent respiratory papillomatosis may now have a new option to reduce the frequency of surgical procedures.

Updated on Oct. 30, 2026 in Cancer

Isometric editorial illustration of geometric cubes representing biological cell interaction, conveying the precision of new medical immunotherapy technology. — The FDA has granted accelerated approval to Voceryq, a new plasmid DNA-based immunotherapy designed to reduce surgical interventions for adults with recurrent respiratory papillomatosis. AI Illustration. Upload story photo >

Live Poll

Do you trust new immunotherapy treatments to be safe for your own health needs?

The FDA has granted accelerated approval to Voceryq, a plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis. The treatment, which targets HPV types 6 and 11, aims to reduce the frequency of surgical interventions for these patients.

Why it matters

Recurrent respiratory papillomatosis is a challenging condition often requiring frequent surgeries, and this new immunotherapy offers a potential way to lower that surgical burden. The drug represents a new approach to managing the condition by stimulating the immune system to target the virus.

In a clinical trial of 32 adults, 27% of those with at least three baseline surgeries required no surgical intervention in the first year following treatment. As an accelerated approval, these findings remain preliminary, and the manufacturer must conduct further trials to confirm clinical benefit.

The players

Inovio Pharmaceuticals, Inc.

A biotechnology company focused on the development of DNA-based immunotherapies and vaccines.

FDA

The federal agency responsible for regulating pharmaceuticals and medical devices in the United States.

The details

Voceryq is a plasmid DNA-based immunotherapy that helps the immune system identify and attack cells infected by HPV types 6 and 11. It is administered through intramuscular injection using the CELLECTRA 5PSP Device, which delivers electrical pulses to create pores in cell membranes, facilitating the drug's entry into the cells. Common side effects reported include injection site reactions, headache, fatigue, hypertension, nausea, and dizziness.

October 30, 2026: The FDA granted accelerated approval for Voceryq.
12 months prior to treatment: Clinical trial participants were evaluated for surgical frequency.

Health Landscape

This approval follows the established framework of the FDA's Accelerated Approval Program, which allows for earlier market access based on surrogate endpoints. It reflects a broader shift toward DNA-based immunotherapies for chronic viral-related conditions.

If you or a loved one manages recurrent respiratory papillomatosis, this new option is worth discussing with your specialist to determine if it aligns with your treatment plan. Because this drug uses a specialized delivery device, care will be concentrated in clinical settings equipped for this administration.

The takeaway

Voceryq offers a new way to potentially reduce the number of surgeries needed for recurrent respiratory papillomatosis. Keep track of your surgical frequency and discuss the potential risks and benefits of this new immunotherapy with your physician to see if it is appropriate for your care.